The Abramson Cancer Center at the University of Pennsylvania was founded in 1973 as an interdisciplinary, interdepartmental research institute of the University of Pennsylvania. Since its inception, the Cancer Center has been continuously funded through the National Cancer Institute (NCI) core Support Grant, receiving five-year renewals in 1984, and 1989, and 1994, and 1999. The Cancer Center has been designated a Comprehensive Cancer Center by the NCI since the early 1970s and was re-designated as a comprehensive Cancer Center by the NCI in 1991. The University of Pennsylvania has had a long and successful track record in terms of scientific leadership, administrative involvement and excellent accrual to clinical trials with the Eastern Cooperative Oncology Group, with continuous funding for more than two decades. In late 2002, the ECOG Principal Investigators Committee reviewed the ECOG participation of the University of Pennsylvania, and found it to be among the strongest academic institutions in the Group, with outstanding scientific and administrative leadership. Data management was found to be good, and accrual acceptable, but continuous improvements in all areas of participation in ECOG activities remain the most important focus of this grant application. The areas in which anticipated improvements are targeted are: institutional support, faculty development, scientific contributions, data management organization and accrual enhancement.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA015488-35
Application #
7276717
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
35
Fiscal Year
2007
Total Cost
$408,759
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75

Showing the most recent 10 out of 120 publications